Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
58.6M
-
Number of holders
-
214
-
Total 13F shares, excl. options
-
63.5M
-
Shares change
-
+1.63M
-
Total reported value, excl. options
-
$2.55B
-
Value change
-
+$81.8M
-
Put/Call ratio
-
0.91
-
Number of buys
-
105
-
Number of sells
-
-103
-
Price
-
$40.14
Significant Holders of AGIOS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (AGIO) as of Q3 2025
272 filings reported holding AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share as of Q3 2025.
AGIOS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (AGIO) has 214 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63.5M shares
.
Largest 10 shareholders include FARALLON CAPITAL MANAGEMENT LLC (5.78M shares), VANGUARD GROUP INC (5.6M shares), BlackRock, Inc. (4.55M shares), Bellevue Group AG (3.71M shares), Erste Asset Management GmbH (2.76M shares), Paradigm Biocapital Advisors LP (2.67M shares), WELLINGTON MANAGEMENT GROUP LLP (2.47M shares), Commodore Capital LP (2.34M shares), STATE STREET CORP (2.26M shares), and MACQUARIE GROUP LTD (1.96M shares).
This table shows the top 214 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.